Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing.

Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing.

BACKGROUND: The plasma total and low-density lipoprotein-cholesterol (LDL-C) levels that are used as diagnostic criteria for familial hypercholesterolaemia (FH) probands in the general population are too stringent for use in relatives, given the higher prior probability of a first-degree relative b...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Starr, B, Hadfield, S, Hutten, B, Lansberg, P, Leren, T, Damgaard, D, Neil, H, Humphries, SE
Format:	Journal article
Język:	English
Wydane:	2008

Podobne zapisy

Statins and familial hypercholesterolaemia.
od: Neil, A, i wsp.
Wydane: (2009)

The effect of adjusting LDL-cholesterol for Lipoprotein(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia
od: D. Thayabaran, i wsp.
Wydane: (2022-10-01)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
od: Marks, D, i wsp.
Wydane: (2006)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
od: Minhas, R, i wsp.
Wydane: (2009)

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study
od: Talmud, P, i wsp.
Wydane: (2013)

A common promoter polymorphism affecting transcription of the MTP-gene influences lipoprotein phenotype in familial hypercholesterolaemia
od: Lundahl, B, i wsp.
Wydane: (1998)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
od: Marks, D, i wsp.
Wydane: (2000)

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
od: Talmud, P, i wsp.
Wydane: (2013)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
od: Marks, i wsp.
Wydane: (2000-01-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
od: Marks, D, i wsp.
Wydane: (2003)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
od: Neil, H, i wsp.
Wydane: (2000)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
od: Marks, D, i wsp.
Wydane: (2002)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
od: Neil, H, i wsp.
Wydane: (2004)

Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia
od: R Dariolo
Wydane: (2008-07-01)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
od: Marks, D, i wsp.
Wydane: (2003)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
od: Humphries, SE, i wsp.
Wydane: (2005)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
od: Neil, H, i wsp.
Wydane: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
od: Neil, H, i wsp.
Wydane: (2004)

Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia
od: Ćwiklińska Agnieszka, i wsp.
Wydane: (2020-01-01)

Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
od: A. David, i wsp.
Wydane: (2023-12-01)

Community-Specific BMI Cutoff Points for South Indian Females
od: K. B. Kishore Mohan, i wsp.
Wydane: (2011-01-01)

Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients.
od: Whittall, R, i wsp.
Wydane: (2010)

Familial hypercholesterolaemia.
od: Gill, P, i wsp.
Wydane: (2012)

Familial hypercholesterolaemia
od: D.J. Blom
Wydane: (2011-01-01)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
od: Seed, M, i wsp.
Wydane: (2011)

Highly Sensitive Cardiac Troponins: The Evidence Behind Sex‐Specific Cutoffs
od: Prerana M. Bhatia, i wsp.
Wydane: (2020-05-01)

Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific
od: Arjen J. Cupido, i wsp.
Wydane: (2022-06-01)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
od: Neil, H, i wsp.
Wydane: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
od: Neil, H, i wsp.
Wydane: (2005)

Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.
od: Rong Na, i wsp.
Wydane: (2013-01-01)

Frequency of Lipoprotein (a) Single Nucleotide Polymorphisms in patients undergoing Familial Hypercholesterolaemia genetic testing
od: D. Reay, i wsp.
Wydane: (2021-09-01)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
od: Neil, A, i wsp.
Wydane: (2003)

Inclisiran for the treatment of hypercholesterolaemia
od: Joel C Marrs, i wsp.
Wydane: (2024-11-01)

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
od: Nherera, L, i wsp.
Wydane: (2010)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
od: Seed, M, i wsp.
Wydane: (2009)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
od: Seed, M, i wsp.
Wydane: (2009)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
od: S.E. Humphries, i wsp.
Wydane: (2023-12-01)

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials
od: Edwards, J, i wsp.
Wydane: (2003)

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials
od: Edwards, J, i wsp.
Wydane: (2003)

Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials
od: Moore R Andrew, i wsp.
Wydane: (2003-12-01)